http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200048509-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab3413f8184feb74be59b7ed962a5b97 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-324 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-304 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-125 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2018-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14c5aedb7f5a428a0557fb0333793466 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb9e529c5ebd38d5f3c00d9ce8271cf5 |
| publicationDate | 2020-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20200048509-A |
| titleOfInvention | Composition for sublingual administration of curdlan inhibiting antigen specific immune responses |
| abstract | The present invention relates to a composition for sublingual administration of curdlan for suppressing an antigen-specific immune response, and specifically, Curdlan, a Dectin-1 ligand derived from Alcaligenes faecalis , 1 , 3-β glucan) when administered by the sublingual route, is directed to an effect that functions as an immunosuppressive modulator. The present inventors have confirmed that the antigen-specific immune response is more effectively inhibited when subcutaneously administered curdlan with the antigen than when administered sublingually with the antigen alone. This proved to be an effect due to the delivery of subcutaneous administration of curdlan when compared to those that induce antigen-specific immune responses as previously known when nasal administration of antigen and curdlan. Through this, it can be used as an immunotherapy method for allergic diseases and autoimmune diseases, which are diseases induced by unnecessary immune responses to allergens and autoantigens. |
| priorityDate | 2018-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 179.